Table 6.
Treatment | Dose (μM) | Number of His+ revertants colonies/plate (mean ± SE) | |||
---|---|---|---|---|---|
TA 97a | TA 98 | TA 100 | TA 102 | ||
Spontaneous | 144.0 ± 8.7 | 39.7 ± 3.8 | 140.3 ± 10.8 | 325.7 ± 16.6 | |
Positive control (BP) | 1.5 μg | 736.7 ± 30.1 | 165.7 ± 10.2 | 704.3 ± 27.0 | 694.0 ± 20.8 |
aEllagic acid | 50 | 142.3 ± 10.7 | 50.0 ± 5.1 | 136.3 ± 12.0 | 336.0 ± 23.0 |
100 | 159.7 ± 10.5 | 44.7 ± 3.8 | 162.7 ± 16.6 | 275.0 ± 16.8 | |
250 | 175.0 ± 15.0 | 38.3 ± 2.3 | 178.0 ± 12.7 | 308.0 ± 17.2 | |
500 | 184.0 ± 10.6 | 32.0 ± 3.6 | 188.7 ± 12.8 | 302.0 ± 17.1 | |
bEllagic acid + BP | 50 | 652.7 ± 35.3 (14.1) | 140.0 ± 12.2 (22.2) | 580.3 ± 25.6* (21.8) | 653.0 ± 34.7 (11.5) |
100 | 529.0 ± 28.6** (36.0) | 107.3 ± 7.9* (48.2) | 472.3 ± 19.4** (42.8) | 595.0 ± 24.1* (23.6) | |
250 | 333.3 ± 22.2*** (71.8) | 86.3 ± 5.8** (62.3) | 336.0 ± 17.6*** (70.0) | 514.0 ± 21.4** (46.6) | |
500 | 275.3 ± 17.5*** (83.5) | 60.7 ± 10.5** (78.6) | 245.7 ± 14.4*** (88.9) | 366.0 ± 25.0*** (83.7) | |
| |||||
R 2 | 098 | 0.97 | 0.99 | 0.93 |
aNegative control; bpreincubation test; values in parenthesis are % inhibition of mutagenicity.
*P < 0.05; **P < 0.005 and ***P < 0.001; B[a]P: benzo[a]pyrene; R 2: linear regression analysis.